New insights into the mode of action of ivermectin against the novel SARS coronavirus.
The previously discussed, WHO-sponsored meta-analysis of ivermectin against covid-19 has now been published as a preprint. It found a highly significant 75% reduction in covid mortality, based on randomized controlled trials only, and will be continually updated with additional trial results.
To date, the mode of action of ivermectin against SARS-CoV-2 has remained somewhat of a mystery. Early studies indicated that ivermectin may inhibit viral protein transportation. But a new US-Canadian study, published in Nature Communications Biology, found that ivermectin is highly effective (>90%) in inhibiting the main enzyme (3CLpro) involved in the replication of SARS-CoV-2 and other RNA viruses (see the chart above).
Another study, submitted to the Journal of Structural Chemistry, found that ivermectin is binding to the spike protein of SARS-CoV-2 and thus may act as a generic antibody. This might explain why ivermectin appears to be highly effective even as a prophylaxis against SARS-CoV-2 infection.
Nevertheless, many patients, and even doctors, continue to be denied access to low-cost and safe ivermectin, especially in Western countries. Others are paying obscenely overcharged prices, visit dubious online merchants, or resort to animal-grade products. If ivermectin is not available locally, it may instead be bought from certified Indian pharmaceutical exporters on Indiamart. However, please note that some countries may not allow its importation.
100 tablets of 12mg ivermectin, enough to treat up to 50 people, cost about $50. And even if SARS-CoV-2 continues to mutate, ivermectin, targeting its replication, should remain effective. The same applies to other early treatment drugs targeting virus entry, replication, or disease progression.
Note: Patients are asked to consult a doctor.